20 November 2019 - Kiniksa Pharmaceuticals today announced that the U.S. FDA granted breakthrough therapy designation for rilonacept for the treatment of recurrent pericarditis. 

Rilonacept is a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and IL-1β signaling.

Kiniksa’s breakthrough therapy application was based on final data from an open-label Phase 2 clinical trial of rilonacept in a range of pericarditis populations that were included in a poster presentation at the American Heart Association Scientific Sessions on 16 November 2019.

Read Kiniksa Pharmaceuticals press release